Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1093/jnci/82.1.66 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Preclinical development of three novel CARs targeting CD79b for the treatment of non-Hodgkin's lymphoma and characterization of the loss of the target antigen.
J Immunother Cancer
December 2024
Department of Experimental Hematology, Health Research Institute of the Jimenez Diaz Foundation, UAM, Madrid, Spain, UAM, Madrid, Spain
Background: Infusion of T cells modified with a chimeric antigen receptor (CAR) targeting CD19 has achieved exceptional responses in patients with non-Hodgkin's lymphoma (NHL), which led to the approval of CAR targeting CD19 (CART19) (Axi-cel and Liso-cel) as second line of treatment for adult patients with relapsed/refractory NHL. Unfortunately, 60% of patients still relapse after CART19 due to either a loss of expression of the target antigen (CD19) in the tumor cell, observed in 27% of relapsed patients, a limited CAR-T persistence, and additional mechanisms, including the suppression of the tumor microenvironment. Clinic strategies to prevent target antigen loss include sequential treatment with CARs directed at CD20 or CD22, which have caused loss of the second antigen, suggesting targeting other antigens less prone to disappear.
View Article and Find Full Text PDF[Solid tumor lysis syndrome: an entity that should not be neglected].
Rev Med Suisse
December 2024
Service de médecine interne, Département de médecine, Réseau hospitalier neuchâtelois, 2300 La Chaux-de-Fonds.
Tumor lysis syndrome is a metabolic emergency resulting from a massive destruction of cancer cells. This is often associated with hematological malignancies, such as non-Hodgkin's lymphoma and acute leukemia, but the incidence tends to increase for solid tumors with the development of oncological treatments. Due to a poor prognosis, it is essential to recognize this syndrome early.
View Article and Find Full Text PDFTemporal changes in the burden of leukaemia and lymphoma in the Australasia and Oceania regions, 2010-2019: an analysis of the Global Burden of Disease Study 2019.
BMJ Open
November 2024
Deakin Health Economics, Deakin University School of Health and Social Development, Burwood, Victoria, Australia.
Article Synopsis
- This study investigates the prevalence and trends of leukaemias and lymphomas in Australasia and Oceania from 2010 to 2019, focusing on key subtypes like AML and NHL.
- Using data from the Global Burden of Disease 2019, the research analyzes incidence, prevalence, disability-adjusted life years (DALYs), and deaths across different age groups and sexes.
- Findings indicate that AML and NHL are the leading cancers in both regions, with Australasia showing overall increases in disease burden during the study period, while Oceania has mixed trends in mortality and prevalence across various leukaemias and lymphomas.
Fluorescent Aerolysin (FLAER) Binding Is Abnormally Low in the Clonal Precursors of Acute Leukemias, with Binding Particularly Low or Absent in Acute Promyelocytic Leukemia.
Int J Mol Sci
November 2024
URSalud Laboratory, Hospital Universitario Infanta Sofia, 28702 San Sebastián de los Reyes, Spain.
Flow cytometry plays a fundamental role in the diagnosis of leukemias and lymphomas, as well as in the follow-up and evaluation of minimally measurable disease after treatment. In some instances, such as in the case of acute promyelocytic leukemia (APL), rapid diagnosis is required to avoid death due to serious blood clotting or bleeding complications. Given that promyelocytes do not express the glycophosphatidylinositol (GPI)-anchored protein CD16 and that deficient CD16 expression is a feature of some CD16 polymorphisms and paroxysmal nocturnal hemoglobinuria (PNH), we included the GPI anchor probe FLAER aerolysin in the APL flow cytometry probe panel.
View Article and Find Full Text PDFGraft-versus-host disease after anti-CD19 chimeric antigen receptor T-cell therapy following allogeneic hematopoietic cell transplantation: a transplant complications and paediatric diseases working parties joint EBMT study.
Leukemia
November 2024
University Hospital Centre Zagreb and School of Medicine, University of Zagreb, Zagreb, Croatia.
In patients diagnosed with B-acute lymphoblastic leukemia (B-ALL) or B-non-Hodgkin's lymphoma (B-NHL) relapsing after allogeneic stem cell transplantation (allo-HCT), it is a standard practice to perform anti-CD19 chimeric antigen receptor (CAR) T-cell therapy. When collected from the patient after allo-HCT, the produced CAR-T cells are likely to be donor T-cell-derived, creating unknown safety risks due to their potential allo-reactivity. We therefore performed an EBMT registry-based study on the incidence of graft-versus-host disease (GvHD) in this setting.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!